-
4.12025 Impact Factor
-
4.52025 5 Year Impact Factor
-
34/141Infectious Diseases (Rank by Impact Factor)
-
8.82025 CiteScore
-
38/361Infectious Diseases (Rank by CiteScore)
Contemporary Research on Antimicrobial Resistance
This special collection of articles were published in The Journal of Infectious Diseases following a call for papers devoted to contemporary research on AMR. The articles cover cutting-edge topics like mechanisms of resistance and virulence, genomics, pharmacokinetics, new drug development and wastewater surveillance, and encompass bacteria, mycobacteria and HIV.
Read now
JID Welcomes Editorial Mentees
The IDSA journals are pleased to announce the mentees participating in the 2026 editorial mentoring program. Elizabeth (Lizzy) Hastie, MD, from the University of California San Diego and Jordan Mah, MD, FRCPC, ABMM, from the Hôpital Maisonneuve-Rosemont and the Université de Montréal will be serving as JID’s editorial mentees. Dr. Hastie and Dr. Mah will work directly with JID editors through January 2027 to gain a deeper understanding of a medical journal editor’s role and work. Our editors are grateful to all who applied and look forward to working with this year’s selected mentees.
Find out more
CID Is Now on Roon!
We’re excited to announce that Clinical Infectious Diseases now has an official presence on Roon, a physician-only social platform to advance knowledge-sharing in medicine.
Follow us for the latest updates, research highlights, and more from CID and the other IDSA journals, and respond to and discuss IDSA and other infectious diseases content with the Roon community.
Follow Clinical Infectious Diseases on Roon

JID Now Offers Review Pathway for Papers Rejected by High-Impact Journals
The Journal of Infectious Diseases welcomes papers that have been peer reviewed by another medical journal and were not accepted for publication, where the authors believe they can address the essential concerns identified by previous reviewers. Under this new pathway, authors can revise the paper according to the review comments they previously received and then submit the paper to JID. This new pathway is intended to speed publication and minimize unnecessary re-review of papers that previously received thorough and detailed review elsewhere.
Learn more about how to submit using this pathway.
Latest Supplements
Explore the latest supplements from JID:
Molecular Epidemiology of β-Lactam Resistance in Gram-Negative Bacteria in China
Read the supplement
Surveillance and Management of Antimicrobial Resistance in Helicobacter pylori in China
Read the supplement
Advances in Influenza Therapeutics
Read the supplement

JID for Clinicians
The Journal of Infectious Diseases has launched JID for Clinicians—a new initiative spotlighting research with relevance to clinical practice. The Editor-in-Chief provides a brief summary of key articles most useful to clinicians, making it easier than ever to stay informed and apply the latest evidence to patient care. Explore this new monthly roundup on the IDSA Science Speaks blog.
Read now
Author Resources
Interested in publishing with JID?
Read the author guidelines to learn more about the JID submission process, and then submit your paper using our online submission system.
Open Access
Authors interested in publishing in JID may be able to publish their paper open access using funds available through their institution's agreement with OUP.
Publishing Process Support
Whether you are preparing your manuscript for submission, are wondering what to do once your manuscript has been accepted or are trying to find out how to promote your article, we have general resources to help you along the way.How to Write a Publishable Manuscript
Watch Dr. Martin S. Hirsch's presentation on writing successful manuscripts.
IDSA Thanks Retiring JID Editors
As the term of Martin S. Hirsch, MD, FIDSA, as editor-in-chief of The Journal of Infectious Diseases ends, the Infectious Diseases Society of America wishes to thank him and all members of his editorial board for their extraordinary work as journal and Society leaders.
Learn more

IDSA Information
The Infectious Diseases Society of America (IDSA) represents physicians, scientists and other health care professionals who specialize in infectious diseases.
Learn more

Stay Connected
The IDSA Journals app gives you the freedom to read The Journal of Infectious Diseases both online and offline, on your iPad, iPhone, or iPod Touch.
Register for email alerts and get notified as soon as new issue is published online.
In this study of cryptosporidiosis and environmental enteric dysfunction biomarkers in 300 Bangladeshi infants, kynurenine–tryptophan ratio was strongly associated with more days of diarrhea among infants, suggesting it may identify children at higher risk of diarrheal morbidity.
There has been little progress in reducing the mortality of pneumococcal pneumonia since the dawn of the antimicrobial era. Further progress in increasing the likelihood of survival in pneumococcal pneumonia is likely to require therapies that help the host.
A very strong El Niño is arriving over a Latin American population with little DENV-3 immunity. Lead time should be used to give first doses, strengthen vector control, differentiate DENV, CHIKV, ZIKV, and OROV outbreaks, and prepare clinical capacity.
Despite the advances following the COVID-19 pandemic, there remain significant gaps in understanding, preventing, and treating the potential long-term, and sometimes life-altering, consequences following infection with acute viral respiratory disease.
There is mounting evidence that Epstein–Barr virus (EBV) infection is the potential cause of multiple sclerosis (MS) [ 1 ]. Epstein–Barr virus exposure is necessary, but insufficient, to develop MS, which explains why most people infected with EBV do not develop MS. Immunologists currently favor ...



